RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)

Next Previous
Trial Profile

RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Eflapegrastim (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Spectrum Pharmaceuticals

    • Most Recent Events

    • 05 Feb 2018 Primary endpoint (Duration of Severe Neutropenia) has been met.
    • 02 Nov 2017 According to a Spectrum Pharmaceuticals media release, the company expects to file BLA in fourth quarter of 2018.
    • 03 Aug 2017 According to a Spectrum Pharmaceuticalsmedia release, topline results from this study are expected in first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top